Alnylam Pharmaceuticals, Inc. announced that Akshay Vaishnaw, M.D., Ph.D. has been appointed President. Dr. Vaishnaw joined the company in 2006 as Vice President, Clinical Research with roles of increasing responsibility, ultimately serving as President of Research and Development (R&D). In this new role, Dr. Vaishnaw will serve as the key scientific leader of Alnylam and will advance the company's R&D strategy focused on sustainable innovation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
249.8 USD | -2.48% |
|
-1.93% | +30.52% |
Jul. 15 | Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing | MT |
Jul. 03 | Jerome Powell did it again | ![]() |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.52% | 31.6B | |
+25.83% | 47.96B | |
+45.38% | 41.47B | |
+0.69% | 42.45B | |
+22.30% | 28.63B | |
-6.35% | 28.03B | |
+49.25% | 14.56B | |
+49.18% | 14.14B | |
+3.45% | 12.58B | |
-3.85% | 11.71B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Announces Promotion of Dr. Akshay Vaishnaw to President